24S-hydroxycholesterol (24OHC) is involved in the conversion of excess cholesterol in the brain, and its level in plasma is related to the number of metabolically active neuronal cells. Previous research suggests that plasma 24OHC is substantially reduced in the presence of neurodegenerative disease. Huntington disease (HD) is an inherited autosomal dominant neurodegenerative disorder caused by a cytosine-adenine-guanine (CAG) triplet repeat expansion in the coding region of the huntingtin (HTT) gene. The current study focused on the relative importance of 24OHC as a marker of HD progression. Using mass spectrometry methods, we examined plasma 24OHC levels in three groups of gene-expanded individuals (Low, Medium, High) characterized by their progression at entry into the parent PREDICT-HD study, along with a group of non-geneexpanded controls (total N = 150). In addition, the correlation of 24OHC with a number of motor, cognitive, and imagining markers was examined, and effect sizes for group differences among the markers were computed for comparison with 24OHC. Results show a progression gradient as 24OHC levels decreased as the progression group increased (Low to High). The effect size of group differences for 24OHC was larger than all the other variables, except striatal volume. 24OHC was significantly correlated with many of the other key variables. The results are interpreted in terms of cholesterol synthesis and neuronal degeneration. This study provides evidence that 24OHC is a relatively important marker of HD progression.
Introduction
Huntington disease (HD) is an inherited autosomal dominant neurodegenerative disorder caused by a cytosine-adenine-guanine (CAG) triplet repeat expansion in the coding region of the huntingtin (HTT) gene (The Huntington's Disease Collaborative Research Group, 1993) . The mutation results in an elongated stretch of glutamine residues located in the NH2-terminal of HTT (Walker, 2007) . Neurodegeneration of the striatum and the cortex is a pathological hallmark of HD with a substantial loss of brain mass, in the order of 30% by the time of death (Vonsattel and DiFiglia, 1998) . This massive neurodegeneration is associated with a progressive striatal and cortical atrophy as measured with MRI (Aylward, 2007; Henley et al., 2009 ) and is evident 10-15 years before motor onset in prodromal (also called pre-manifest) gene-expanded participants (Paulsen et al., 2008) . The identification of mutation carriers provides the opportunity to investigate early disease mechanisms and, ideally, to find therapeutic strategies to halt disease progression prior to symptom onset (Weir et al., 2011) .
In the early stages of the disease course, a progressive neuronal dysfunction is associated with cognitive, sensory and motor impairment. Later on, progressive cell death in vulnerable regions of the brain becomes correlated with motor signs and other functional disabilities (Ross and Tabrizi, 2011). Subtle and minor motor signs of HD are evident several years before a formal diagnosis. Together with measurable cognitive impairments these clinical findings link with neurobiological changes such as striatal atrophy (Ross and Tabrizi, 2011) . PET blood flow analyses and functional MRI studies in prodromal individuals reveal reduced activation patterns in the basal ganglia (Harris et al., 1999) and cingulate cortex (Aylward et al., 2004) , in the absence of volumetric losses, as well as reduced neural activation (Zimbelman et al., 2007) . Reduction in raclopride (D2 dopamine receptor) binding at PET scanning has also been shown in asymptomatic mutation carriers (Weeks et al., 1996) . In total, these findings suggest that abnormalities in cell function may be detectable much earlier than objective signs of cell death.
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